SWOG clinical trial number
SWOG-7925

Chemoimmunotherapy in Stages III & IV Ovarian Carcinoma: A-C Plus BCG Vs. A-C Plus Cis-Platinum Vs. A-C Plus BCG

Closed
Phase
Published
Abbreviated Title
Chemoimmunotherapy in Stages III & IV Ovarian Carcinoma: A-C Plus BCG Vs. A-C Plus Cis-Platinum Vs. A-C Plus BCG
Activated
08/06/1979
Closed
03/16/1984

Publication Information Expand/Collapse

2009

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

1989

Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III & IV suboptimal disease ovarian cancer: A Southwest Oncology Group Study.

DS Alberts;N Mason-Liddel;RV O'Toole;TM Abbott;R Kronmal;RD Hilgers;EA Surwit;HJ Eyre;LH Baker Gyn Onc 32:8-15

1986

Randomized Phase III trial of doxorubin (D) + cyclophosphamide (C)+ BCG vs. DC + cisplatin (P) vs. DC +P + BCG in stages III & IVovarian cancer (OV CA).

D Alberts;N Mason;R O'Toole;R Kronmal;R Hilgers;E Surwit;H Eyre;L Baker;J Boutselis;S Rivkin;B Green;E Hannigan ASCO 5:119(#462)